Minireview

Optimising Treatment of End-Stage Renal Disease in the Elderly

Albert Power    Edwina Brown

Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, UK

Background

It is not surprising that the dialysis population is ageing given the ageing general population and the fact that chronic kidney disease prevalence increases with age. In the UK, the dialysis population of adults aged ≥65 years grew by 29% from 2005 to 2008 compared to only 16% in those aged 18–65 years [1, 2]. In the USA from 2005 to 2008, the highest growth rate was seen in the oldest old (≥85 years) [3]. Dialysis for the older and frailer individual is a comparatively new treatment option. As late as 1984, Challah et al. [4] reported from a survey that 45% of a sample of UK nephrologists would decline dialysis in a 50-year-old man with ischaemic heart disease. Less than 20 years later outcomes of octogenarians on dialysis were being published [5]. This first major report of outcomes in the ‘old elderly’ focused on survival as the outcome measure with a median survival of 28.9 months. More recent papers have focused on physical function as well as survival. Longitudinal data of 97 patients >80 years from Toronto showed that whereas 75% of patients at the start of dialysis were functionally independent and living at home, within 6 months 30% required community support or transfer to a nursing home. At 12 months only
22% of this cohort were still alive and independent [6]. Of 3,700 nursing home residents starting haemodialysis (HD), only 15% were alive and had maintained their physical function at 12 months [7].

As a population, older patients with advanced chronic kidney disease have a tendency to present later for dialysis [8], have a higher number of comorbid conditions, are at higher risk of cognitive dysfunction [9] and have increased levels of frailty [10], all combined with potential sensory impairments such as declining vision [11]. Nutrition is also often a major problem for these patients. All these factors make any treatment modality difficult for older patients with end-stage renal disease (ESRD). Although age itself is no longer a contraindication to transplantation and access to transplantation for the elderly has increased over time [12], the majority will have too much comorbidity to be eligible, or will develop complications precluding transplantation while waiting for a kidney. Most older patients on renal replacement therapy are therefore on dialysis for the remainder of their life. With appropriate education many older patients prefer a home-based treatment, with around 60% choosing peritoneal dialysis (PD) [13]. ERA-EDTA registry data, in contrast, show that in comparison to patients aged 20–44 years, those ≥70 years old are 56% less likely to receive PD as compared to HD [14]. In 2009, according to UK Renal Registry data, 26.9% of patients starting dialysis <65 years of age were on PD, but only 14.2% of those ≥65 years [2]. This relatively low use of PD in the elderly occurs despite the obvious advantages for the fit and frail older person. For the fit elderly, PD enables travel, an active social life, continuing working, care for grandchildren, etc. The frail elderly often tolerate HD poorly because of haemodynamic instability and require transportation to and from dialysis. PD can avoid these difficulties.

Therefore, there is an urgent need to improve treatment of ESRD in the elderly. In this review, we shall focus on some specific areas which may improve the patient experience for older patients on dialysis, namely choice of dialysis modality, HD treatment, development of assisted PD (aPD) and transplantation. Finally, we shall consider the choice not to have dialysis, i.e. conservative care. As already discussed, outcomes on dialysis for older patients with multiple comorbidities are often very poor and it can appear that being on dialysis is extending the period of dying rather than providing any improvement in quality of living. It is therefore not surprising that there is a debate whether dialysis should be considered in very frail individuals [15].

### Quality of Life and Dialysis Modality

Remarkably, there are only two studies comparing quality of life (QoL) on HD and PD: the North Thames Dialysis Study [16, 17] and Broadening Options for Long-Term Dialysis in the Elderly (BOLDE) [18]. The North Thames Dialysis Study was carried out in the late 1990s when 40% of the patients were on PD in the UK; it was a prospective study of incident and prevalent patients starting on dialysis over the age of 70 years and showed that outcomes – survival and QoL – were not different for patients on HD and PD. BOLDE is a recently completed study in the same UK centres, the first part of which has focused on QoL. The principal aim of the study is to enable older patients to receive the dialysis modality of their choice. As there was so little literature about QoL, the first part of the study determined QoL, depression, symptoms and illness intrusion in older (≥65 years) patients [18]. Seventy PD patients were compared to HD patients matched by age, gender, length of time on dialysis, ethnicity and socioeconomic status. The QoL measures used were the SF-12, Hospital Anxiety and Depression Scale and the Illness Intrusiveness Ratings Scale. After regression analyses, modality was found to be an independent predictor only of illness intrusion with greater intrusion felt in those on HD. BOLDE has therefore shown that older patients can successfully manage PD and that in two closely matched demographic groups of older dialysis patients on PD and HD, QoL was similar, but with significantly less perception of illness intrusion in the PD group.

### Modality Education and Choice

As we have discussed above, many older patients could be eligible for home dialysis options, particularly if assistance is available. During the pre-dialysis phase while in nephrology clinics, they should have been provided with education to enable them to participate in the decision regarding the most appropriate dialysis modality for them. If we consider the wider context of governmental goals for encouraging health benefits for the UK population, involvement in treatment decisions is certainly a focal point [19]. The choice of dialysis modality is a prime example where shared decision-making should result in the patient’s personal values being matched with the medical characteristics of the treatment in order to maximise achievable QoL [20]. Even in locations where dialysis modality options exist, these may not always be presented in an appropriate manner to the older patient.
Written information from renal units is often complex and difficult to understand [21], hindering decision-making in a group already vulnerable to comprehension errors [22] and low healthcare literacy [23]. Increasing age has also been found to be associated with fear that home-based treatments were substandard compared to in-centre dialysis in a sample of HD patients [24]. It is therefore not surprising that some older people are more likely to prefer the healthcare team to make treatment decisions although there is wide variation in this [25]. There is also evidence that healthcare teams will respond by taking dialysis treatment decisions on behalf of older patients [26]. There is therefore a real risk within this patient group that the modality favoured by the renal team becomes the treatment of choice.

In addition to facilitating the choice of modality and ensuring timely dialysis access placement, the purpose of dedicated pre-dialysis care is to optimise the patient physically as well as psychosocially for their period of time on renal replacement therapy. For example, medicine management with tailored prescription is advisable to avoid unnecessary polypharmacy and its attendant hazards [27]. Judicious erythropoietin dosing as part of anaemia management could help in reducing stroke incidence in a population at the highest risk [28]. Dialysis initiation in the elderly is associated with a progressive loss of functional independence, which is particularly marked in nursing home residents [7, 29]. Appropriate multidisciplinary symptom management can lead to preservation of functional ability and also avoid unnecessarily early dialysis initiation for non-uraemic symptomatology [27, 30]. Individualised nutritional and dietetic interventions coupled with physiotherapy regimes may lead to better functional status and core strength over time, reduce the incidence of falls and improve well-being in a particularly vulnerable group of people [31, 32]. Although there are no trial data to support the use of such preparatory interventions, achieving an optimal physical and psychological state may influence the timing of dialysis initiation especially in the frail elderly who stand to benefit the most.

**Haemodialysis**

European registry data demonstrates that patients aged >70 years are 56% less likely to start with PD compared to HD which remains the dominant modality in elderly patients [14], reaching 86% of incident patients aged ≥65 years in the UK [33]. It is therefore important to understand the direct impact this treatment has on the physical and psychosocial health of older people and how clinical practice can be improved.

The elderly on HD represent a physically frail patient group with multiple comorbid conditions and functional dependencies. In a recent report from the Dialysis Outcomes and Practice Patterns Study (DOPPS), 46–55% of patients aged ≥75 years had coronary artery disease, 25–30% cerebrovascular disease, and up to 50% had congestive cardiac failure and peripheral vascular disease [34]. Older patients are more prone to intradialytic hypotension [35], which may relate to myocardial dysfunction and impaired autonomic function [36]. The intradialytic reduction in myocardial blood flow seen during HD [37] could further worsen haemodynamic instability resulting in repeated cycles of end-organ hypoperfusion. This may underpin the heightened predisposition to falls [38, 39], cardiac events, cerebral dysfunction and stroke [40, 41], malnutrition-inflammation syndrome [42], and loss of residual renal function [43] that is seen in older HD patients. Tailored dialysis prescription using an appropriate target dry weight aided by bioimpedance analysis [44] and the use of judicious, slower, feedback-controlled ultrafiltration with lowered dialysate sodium concentrations (<140 mmol/l) [45] can help maintain intradialytic haemodynamic stability in conventional HD schedules. Cooled dialysate, where tolerated, can promote blood pressure stability [46], and more frequent HD regimes (e.g. short daily or nocturnal) may also be used with good effect [47]. We advise caution in the use of vasoconstrictors (e.g. midodrine) to treat symptomatic hypotension given the high prevalence of vascular disease in this population [48].

In comparison to younger populations, there is a higher prevalence of central venous catheter use in the elderly [49], an access form independently associated with a greater risk of death [50]. Although it is believed that age is a risk factor for poor maturation of arteriovenous fistulae, recent series have shown that this is not the case [51, 52], and more effort should be made to promote this form of vascular access in a group of patients that often receives less pre-dialysis care than their younger counterparts [53].

Forty percent of patients in DOPPS were unable to walk without assistance [34], and up to 75% of the elderly on dialysis fulfil criteria for frailty that itself portends an adverse prognosis [10]. The lifestyle restrictions of thrice weekly in-centre HD coupled with potentially long and arduous transport times can be significant for elderly patients and influence choice of modality [54]. Conventional HD can exacerbate functional impairment by leaving patients feeling exhausted and worn-out with a long
‘time to recovery’ [55], an effect attributed to intradialytic haemodynamic changes and transient biochemical disequilibrium [56], and which can be mitigated by slow daily HD as a home-based treatment [57]. Appropriate multidisciplinary pre-dialysis education can reduce 1-year morbidity in incident patients [57] and targeted rehabilitation programmes are able to improve functional status in elderly patients with new-onset disability allowing over 70% of those affected to return to their private homes [58]. One study of 271 patients admitted to a nursing home for rehabilitation demonstrated that staff-assisted HD is feasible and can allow for successful home discharge in 40% of the cases [59].

Transplantation

Transplantation remains the optimal mode of renal replacement therapy and is associated with a significant survival advantage in younger populations and improved QoL. This survival advantage is also seen in elderly (>70 years) US transplant recipients compared to matched patients on a transplant waiting list (41% reduced risk of death) [60], although this relative benefit may be less marked in countries with better dialysis survival than the US and appears to wane with increasing dialysis vintage [61]. However, older age is associated with increased comorbidity and decreased functional ability that can itself preclude transplantation. In addition, the probability of receiving a cadaveric graft declines with increasing age: only 8% of wait-listed patients aged 65–75 years in the UK were transplanted within 5 years of listing in one study [62]. Allocation schemes such as the Eurotransplant Senior Programme have been developed to improve access to age-matched organs for patients ≥65 years old and have yielded results comparable to those via conventional allocation schemes [63].

Although numerous studies have shown that older age per se does not adversely influence allograft outcomes [64], data suggest higher rates of surgical complications in elderly recipients [65, 66] and caution is advised regarding the intensity of immunosuppression and the attendant risk of infectious complications [67] and post-transplant malignancy [68]. There are few, heterogeneous studies examining the impact of transplantation on QoL in elderly recipients and those undergoing transplantation represent a highly selected group manifesting a degree of physical health and psychological motivation. Early and careful assessment of fitness for transplantation is required to facilitate appropriate transplant listing in the elderly. In addition, given the scarcity of donor organs, living donation should be promoted and can be both feasible and successful [69].

Assisted Peritoneal Dialysis

Realistically, few frail elderly patients will be able to perform their own PD. In some instances, family members will help, but usually, when this is not possible, patients are placed on HD with all its difficulties, and some will opt for conservative care, i.e. no dialysis. In recent years, various models of aPD have evolved to enable this group of patients to have PD in their own homes. The longest and largest experience of aPD is in France, where PD is predominantly a treatment of the elderly, with more than 50% of PD patients being over 70 years of age [70]. A recent analysis by the French REIN registry of 3,512 patients over 75 years starting dialysis between 2002 and 2005 showed that 18% began with PD, with the proportion varying from 3 to 38% depending on region; over half of these patients were on aPD [71]. aPD is being developed in many other parts of Europe using various models of care [72]. Experience from Toronto suggests that availability of assistance can increase the proportion of patients considered to be eligible for PD [13]. This study also showed that adverse events (e.g. hospitalisations and death) were no different between patients on aPD and other dialysis modalities in older people. There is no data about QoL or patient outcomes on aPD compared to HD; this is being addressed by the Frail and Elderly Patient Outcomes on Dialysis (FEPOD) study which will report its initial results in 2014.

Conservative Care

Given the poor outcomes of many old and frail patients with multiple comorbidities on dialysis, it is not surprising that there is a debate whether non-dialysis management would be more humane [15]. In the UK, conservative care, or maximum management without dialysis, has increasingly been offered and is not infrequently chosen by older and frail patients [73, 74]. In Australia a recent study suggests that 14% of patients with chronic kidney disease stage 5 choose conservative care; not surprisingly, this group was elderly with a median age of 80 years [75]. Such patients continue to be followed in renal clinics with active management focusing on anaemia, fluid status and symptom control. It is difficult to determine
survival on conservative care as there is no definite start as there is with dialysis. Using a fixed GFR prior to starting dialysis as the start point, studies have suggested that there is no difference in survival of older patients with multiple comorbidities or poor physical function on conservative care and dialysis [73, 74, 76]. Indeed, there is a suggestion that some patients >75 years with high comorbidity could actually live longer than those on dialysis [74]. There are no studies comparing QoL on conservative care and dialysis, but recent evidence suggests that conservative care patients maintain their level of physical function for their last year of life until a sharp decline in the last month [77], in comparison to the functional decline that occurs in many frail elderly patients after starting dialysis [6, 7]. Conservative care patients are also more likely to die at home or in a hospice and spend fewer days in hospital than those on dialysis [78].

**End-of-Life Management**

Median survival for patients >75 years starting on dialysis is short – around 2.5 years according to UK Renal Registry data [2]. Management of older patients with ESRD should therefore include discussions about realistic outcomes from interventions – not just dialysis, but also management of comorbidity. Patients will have different goals and attitudes to the extent of treatment they wish and this should be ascertained as part of shared decision-making [79]. A recent study by Schell et al. [80], however, shows that nephrologists often do not discuss prognosis with their elderly patients. The UK General Medical Council guidance on end-of-life care (2010) states that doctors must ensure that death becomes ‘an explicit discussion point when patients are likely to die within 12 months, and that medical paternalism on the subject, however benignly intended, must be replaced by patient choice’ [81]. For prevalent HD patients, a prognostic tool for the end-of-life phase has been developed based on five variables, namely older age, dementia, peripheral vascular disease, decreased albumin and the answer ‘no’ to ‘would you be surprised if the patient died in the next 6 months?’ [82]. Most models for transition to palliative care recommend a phased approach with a gradual change in focus from cure or active management of a chronic disease to ‘supportive’ management with the focus of care being on maximising QoL. This should include identifying and managing symptoms [83], including pain [84], mental health issues, particularly depression [85], and being aware of spiritual needs [86].

**Conclusion**

As the numbers of older people developing ESRD continue to rise, we need to evolve treatment patterns that focus on patient-orientated outcomes. This involves integration between nephrologists, medicine for the elderly and palliative care specialists, primary care in the community and social care. For too long, survival has been the main outcome measure by which we have assessed different renal replacement treatment modalities; this is easy to measure but completely ignores the QoL of the individual on that therapy. In any case, there is little evidence that there is any significant survival advantage between HD, PD, and transplantation for older patients – and for the frail elderly, no survival advantage between dialysis and non-dialysis. Management should therefore be individualised for each patient depending on their lifestyle goals and their understanding of realistic outcomes for each treatment modality. We should move away from the default position of treatment with in-hospital HD. This denies the rights of fitter older patients to the independence associated with home treatment and can result in dramatic reduction in physical function for older frail patients. Development of assisted PD would also enable more frail patients to have their treatment at home. This approach will result in better care for our patients and will limit the use of inappropriate and futile intensive and intrusive treatments as patients approach the end of their life.

**References**


87 Power/Brown

DOI: 10.1159/000357433